Tribbles homolog 2 promotes hepatic fibrosis and hepatocarcinogenesis through phosphatase 1A‐Mediated stabilization of yes‐associated protein

Dejuan Xiang,Xiaoyun Zhu,Yanqiu Zhang,Jie Zou,Jie Li,Lingyi Kong,Hao Zhang
DOI: https://doi.org/10.1111/liv.14782
IF: 8.754
2021-01-10
Liver International
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background &amp; Aims</h3><p>Hepatic stellate cells (HSCs) play critical roles in liver fibrosis and hepatocellular carcinoma (HCC). Tribbles homolog 2 (TRIB2) is an oncogene implicated in a variety of cancers, including liver cancer. However, the biological function and regulatory mechanism of TRIB2 in HSCs are poorly understood. In addition, little is known about its role in liver fibrosis progression to HCC. Here, we revealed the clinical significance of TRIB2 in liver fibrosis and HCC development.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>we investigated TRIB2 promoting liver fibrosis <i>in vitro</i> and <i>in vivo</i>. In mouse model of liver fibrosis and HCC, we measured hepatic fibrosis and HCC level through knockdown TRIB2 with shRNA. In addition, we performed western blotting, real‐time quantitative PCR, immunofluorescence and co‐immunoprecipitation assay to study TRIB2 function in LX‐2 cells. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>TRIB2 expression was strongly upregulated in human fibrotic liver tissues and HCC tissues. TRIB2 colocalized withα‐smooth muscle actin (α‐SMA) in fibrotic and HCC liver tissues. Knockdown of TRIB2 inhibited HSC activation and liver fibrosis <i>in vitro</i> and <i>in vivo</i>. TRIB2 promoted Yes‐associated protein (YAP) stabilization, nuclear localization, and subsequent fibrotic gene expression independent of the MST‐LATS phosphorylation cascade in HSCs. TRIB2 interacted with YAP to recruit phosphatase 1A (PP1A), promoting PP1A‐mediated YAP dephosphorylation. TRIB2 knockdown potently attenuated the development of fibrosis‐associated liver cancer. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>TRIB2 is an attractive target for hepatic fibrosis and fibrosis‐associated liver cancer treatment.</p></section>
gastroenterology & hepatology
What problem does this paper attempt to address?